Abstract
Adoptive cellular therapy is becoming an important cancer therapy. Tumor infiltrating T cells and peripheral blood T cells engineered to express high affinity T cell receptors specific to tumor antigens have been effective in treating melanoma. T cells engineered to express chimeric antigen receptors are being used to treat cancers and hematologic malignancies. Clinical studies have found that the characteristics of cellular therapies effects clinical outcomes. There is considerable variability between production lots of adoptive cellular therapies. This variability affects product characteristics and clinical outcomes. Production variability is due to both donor and manufacturing factors. Donor genetics as well as donor age, gender, race and prior therapies may affect product characteristics and function. The complexity involved with manufacturing cellular therapies also contributes to variability in the final product. Manufacturing adoptive cell therapies may involve stimulation with antibodies, cytokines, growth factors or allogeneic cells; prolonged culture and expansion; and genetic engineering. Product characteristics can affect clinical outcomes. Several studies have found that adoptive cellular therapies that have greater in vivo persistence and proliferation are associated with better clinical outcomes; however, the specific product characteristics responsible for better or worse clinical outcomes are not well understood. To better understand the critical characteristics responsible for the clinical effectiveness of cellular therapies we and others have been studying the potency of cellular therapies. Specific phenotypes have been associated with better clinical outcomes. Animal models suggest that T memory stem cells have greater proliferative potential and persistence than effector T cells and are more effective for adoptive cellular therapy. We have found that high throughput molecular assays are useful at identifying markers that are useful at measuring cell potency. In conclusion, in order to improve the clinical effectiveness of cellular therapies it’s important to better understand the biological functions that contribute to product potency and develop potency markers and assays to ensure that the highest quality cells are consistently produced.
Highlights
Convenient online submission Thorough peer review No space constraints or color figure charges Immediate publication on acceptance Inclusion in PubMed, CAS, Scopus and Google Scholar Research which is freely available for redistribution
Tumor infiltrating T cells and peripheral blood T cells engineered to express high affinity T cell receptors specific to tumor antigens have been effective in treating melanoma
Several studies have found that adoptive cellular therapies that have greater in vivo persistence and proliferation are associated with better clinical outcomes; the specific product characteristics responsible for better or worse clinical outcomes are not well understood
Summary
Advances in adoptive cellular therapy of cancer From Melanoma Bridge Meeting 2014 Naples, Italy. Adoptive cellular therapy is becoming an important cancer therapy. Tumor infiltrating T cells and peripheral blood T cells engineered to express high affinity T cell receptors specific to tumor antigens have been effective in treating melanoma.
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
